Location History:
- München, DE (2001)
- Munich, DE (2003)
- Ihringen, DE (2007 - 2010)
Company Filing History:
2 out of 10 
1 out of 47 
1 out of 2,943 
Years Active: 2001-2010
Title: Christoph Gibson: Innovating in Integrin Inhibitor Compounds
Introduction
Christoph Gibson, an innovative inventor based in Ihringen, Germany, has made significant contributions to the field of biomedical engineering and pharmacology with a total of four patents to his name. His work primarily focuses on peptide and peptide mimetic compounds that serve as integrin inhibitors, showcasing his dedication to addressing critical health issues.
Latest Patents
Christoph Gibson's latest patents include groundbreaking compounds with integrin-inhibitor properties. His first patent describes peptides and peptide mimetic conjugates represented by the formula (1) B-Q-X, where B signifies a bioactive cell adhesive mediating molecule, Q can be absent or an inorganic spacer molecule, and X is an anchor molecule. These compounds are designed for treating a variety of medical conditions, including osteoporosis, thrombosis, cardiac infarction, and arteriosclerosis, as well as enhancing the integration process of implants into tissue.
The second patent also focuses on peptide and peptide mimetic derivatives with similar integrin-inhibitor properties. The formula includes a selection of bioactive cell adhesive mediating molecules. The innovative compounds aim to alleviate illnesses and deficiencies associated with osteolytic diseases and improve biocompatibility in tissue integration.
Career Highlights
Christoph Gibson has a distinguished career, having worked with renowned companies such as Biomet Deutschland GmbH and Merck Patent Gesellschaft mbH. His involvement in these organizations has allowed him to refine his expertise and contribute to significant advancements in patentable technologies within the healthcare sector.
Collaborations
Throughout his career, Christoph has collaborated with esteemed colleagues, including Horst Kessler and Günter Hölzemann. Their combined efforts in research and development have propelled many projects toward innovation and commercial viability.
Conclusion
Christoph Gibson's dedication to developing peptide-based technologies has positioned him as a pivotal figure in the innovation of integrin inhibitors. His patents reflect a commitment to improving medical treatments and enhancing the quality of life for patients suffering from various health challenges. Through his collaborations and work in notable companies, he continues to push the boundaries of scientific discovery and innovation.